Not known Facts About Imipenem
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Key trial goals were To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients